Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria

BACKGROUND: The administration of calcineurin inhibitors (CNIs) posttransplant has been implicated as an independent risk factor for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT). The new immunosuppressive agent sirolimus (SRL) acts as a primary immunosuppressant...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Transl Med
Glavni autori: Ling, Sunbin, Feng, Tingting, Zhan, Qifan, Duan, Xin, Jiang, Guangjiang, Shen, Tian, Shan, Qiaonan, Xu, Shengjun, Ye, Qianwei, Liu, Peng, Cen, Beini, Zheng, Shusen, Xu, Xiao
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049005/
https://ncbi.nlm.nih.gov/pubmed/32175373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.01.10
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items